Objective To explore the effects of angiolensin convening enzyme inhibilor( ACEI) Benazepril Hydrochloride Tablels on perilioneal funclion and whelher this ACEI is proleclive in periloneal dialysis palienls. Methods Filly ESRD palienls undergoing regular conlinuous ambutatory periloneal dialysis( CAPD) were randomly assigned to Benazepril Hydrochloride Tablels( 10mg/d, n = 25) group or conlrol group( n = 25) . During the 12 monlhs, at least 2 perilioneal equilibration lesls( PET) were performed. In all palienls the e-GFR and 24h urinary volume and daily ullrafillralion volume were delecled before and after the experiment The Kt/V was lesled after 12 monlhs. The expression of transforming growth faclor-β1( TGF-β1) and vascular endothelial growth factor( VEGF) in the overnight effluent were examined by enzyme-linked immunosorbent assay( ELISA) before and after the experiment. Result At the beginning of treatment, no difference in residual renal function was found between Benazepril Hydrochloride Tablets group and control group. 12 months later, the residual renal function decreased in both groups, but it reduced more in the control group( P <0. 01) . The transforming growth factor-β1 and vascular endothelial growth factor increased in both groups, but it increased more significantly in the control group( P<0.01) . Conclusion Benazepril Hydrochloride may effectively protect against peritoneal fibrosis and reduce the rate of decline of residual renal function in patients with regular peritoneal dialysis.%目的 探讨血管紧张素转换酶抑制剂(ACEI)盐酸贝那普利对腹膜透析患者腹膜功能的影响及能否保护其残余肾功能.方法 将入选的50例病情稳定的维持性腹膜透析患者随机分为两组,盐酸贝那普利组和对照组各25例,盐酸贝那普利组予盐酸贝那普利10 mg/d.观察期12个月,研究开始和结束时均行腹膜平衡实验(PET),测定残余肾功能(RRF),记录24 h尿量、日超滤量.研究结束时测定尿素清除指数(Kt/V).研究前后以酶联免疫法(ELISA)检测患者过夜腹透液中的转化生长因子β1(TGF-β1)和血管内皮生长因子(VEGF).结果 盐酸贝那普利组和对照组的残余肾功能起始时没有明显差别,12个月后两组的残余肾功能均下降,但对照组下降更明显,差异有统计学意义(P<0.01).两组患者过夜腹透液中TGF-β1和VEGF表达水平均升高,而对照组两种因子表达水平升高较盐酸贝那普利组更明显,差异有统计学意义(P＜0.01).结论 持续性非卧床腹膜透析患者长期使用盐酸贝那普利可抑制透析液中TGF-β1、VEGF的表达,保护腹膜功能,并能延缓残余肾功能下降.
展开▼
